Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.09
-0.00 (-2.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.4M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
N/A
•EV/EBITDA
10.7x
↓ROE
-1.7%
↓Gross Margin
71.1%
↑Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+29.4%
FCF CAGR
—
FCF margin
-2.3%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42.4M · net income $-1.4M · FCF $-960000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42.4M | $42.4M | $36.8M | $25.6M | $19.6M |
| Net Income | $-1.4M | $-1.4M | $3.3M | $-8.2M | $-9.2M |
| EBITDA | $2.7M | $2.7M | $-742000.00 | $-4.5M | $-4.6M |
| EPS | -0.00 | -0.00 | 0.01 | -0.03 | -0.04 |
| Gross Margin | 71.1% | 71.1% | 68.6% | 51.2% | 61.2% |
| Operating Margin | 5.0% | 5.0% | -9.6% | -47.8% | -68.9% |
| Net Margin | -3.3% | -3.3% | 9.0% | -31.8% | -47.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.05 | 0.07 | 0.14 |
| Current Ratio | 3.48 | 3.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-960000.00 | $-960000.00 | $-1.6M | $-1.4M | $-11.9M |
| Returns | |||||
| ROE | -1.7% | -1.7% | 3.9% | -10.6% | -11.2% |
| Valuation | |||||
| P/E | — | — | 10.91 | — | — |
| EV/EBITDA | 10.74 | 10.74 | — | — | — |
| P/B | 0.31 | 0.31 | 0.43 | 0.54 | 0.55 |
| Growth & Yield | |||||
| Revenue Growth | 15.2% | 15.2% | 43.7% | 31.0% | — |
| EPS Growth | -141.8% | -141.8% | 140.4% | 26.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.01 → -0.00
Residual
-22.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.